Biopharmaceutical leader Kiniksa Pharmaceuticals (KNSA) is approaching a new buy point in the wake of a strong quarterly sales report. That makes Kiniksa stock Thursday's pick for IBD 50 Growth Stocks To Watch from Investor's Business Daily.
Kiniksa develops and commercializes medicines for cardiovascular, autoimmune and autoinflammatory diseases. Its only drug, Arcalyst, treats recurrent pericarditis, a condition in which the sac protecting the heart, the pericardium, becomes inflamed. The risk of recurrence increases with each subsequent flare-up of pericarditis, according to the Arcalyst website.
The company expects to replace Arcalyst with a next-generation version, now called KPL-387, in 2028 or 2029.
While Arcalyst requires a weekly under-the-skin shot, KPL-387 is a monthly injection. KPL-387 sales are expected to start slow at $21.7 million in 2028, growing to $173.7 million, $486.3 million and $1.03 billion over the next three years.
During the second quarter, Arcalyst generated $243.6 million in sales, growing 55% year over year. That crushed estimates from FactSet that called for $227.7 million.

#next #biopharmaceutical